CN Patent

CN119421712A — 用于多发性硬化和重症肌无力的治疗性酪氨酸激酶抑制剂

Assigned to Principia Biopharma Inc · Expires 2025-02-11 · 1y expired

What this patent protects

本公开文本涉及如下领域：用于治疗患有MG或MS的患者的治疗性酪氨酸激酶抑制剂，特别是布鲁顿酪氨酸激酶(“BTK”)抑制剂。

USPTO Abstract

本公开文本涉及如下领域：用于治疗患有MG或MS的患者的治疗性酪氨酸激酶抑制剂，特别是布鲁顿酪氨酸激酶(“BTK”)抑制剂。

Drugs covered by this patent

iptacopan-hydrochloride (IPTACOPAN HYDROCHLORIDE)

Patent Metadata

Patent number: CN119421712A
Jurisdiction: CN
Classification: —
Expires: 2025-02-11
Drug substance claim: No
Drug product claim: No
Assignee: Principia Biopharma Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.